help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Biermasz, N. R.
Right arrow Articles by Roelfsema, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Biermasz, N. R.
Right arrow Articles by Roelfsema, F.
The Journal of Clinical Endocrinology & Metabolism Vol. 84, No. 10 3551-3555
Copyright © 1999 by The Endocrine Society


Original Studies

Direct Postoperative and Follow-Up Results of Transsphenoidal Surgery in 19 Acromegalic Patients Pretreated with Octreotide Compared to Those in Untreated Matched Controls

N. R. Biermasz, H. van Dulken and F. Roelfsema

Department of Endocrinology, Leiden University Medical Center, 2333AA Leiden, The Netherlands

Address all correspondence and requests for reprints to: Dr. F. Roelfsema, Department of Endocrinology, Leiden University Medical Center, Albinusdreef 2, 2333 AA Leiden, The Netherlands.

In this study 19 patients were preoperatively treated with octreotide for 1–17 months (mean, 5 months), with doses from 150–1500 µg daily, and those patients were matched to 19 untreated patients with comparable tumor classification and preoperative serum GH concentrations. Octreotide was started at 300 µg daily by sc injections or continuous sc infusion using a pump in increasing doses, depending on the responses of the serum GH and insulin-like growth factor I (IGF-I) concentrations. During pretreatment, seven patients achieved a serum GH concentration below 5 mU/L, whereas six patients normalized their serum IGF-I.

Postoperatively, a serum GH concentration below 5 mU/L was achieved in 15 pretreated and 14 untreated patients, a normal serum IGF-I level (<2 SD) was achieved in 10 pretreated and 15 untreated patients, and normal serum GH suppression during GTT was reached in 12 treated and 14 control patients. No differences were found in complication rate or incidence of hypopituitarism caused by surgery.

Adjuvant therapy was required in 7 treated and 5 untreated patients. At follow-up examination, 5.7 and 4 yr postoperatively, 10 pretreated and 12 control patients could be considered cured by surgery only, according to our criteria for remission (serum GH, <5 mU/L; normal GH suppression and normal serum IGF-I). In summary, we found no difference in direct postoperative and follow-up results of transsphenoidal surgery between pretreated patients and untreated patients. This finding is in discordance with other studies, which have claimed a beneficial effect of octreotide pretreatment.




This article has been cited by other articles:


Home page
J. Clin. Endocrinol. Metab.Home page
A. Beckers
Does Preoperative Somatostatin Analog Treatment Improve Surgical Cure Rates in Acromegaly? A New Look at an Old Question
J. Clin. Endocrinol. Metab., August 1, 2008; 93(8): 2975 - 2977.
[Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
S. M. Carlsen, M. Lund-Johansen, T. Schreiner, S. Aanderud, O. Johannesen, J. Svartberg, J. G. Cooper, J. K. Hald, S. L. Fougner, J. Bollerslev, et al.
Preoperative Octreotide Treatment in Newly Diagnosed Acromegalic Patients with Macroadenomas Increases Cure Short-Term Postoperative Rates: A Prospective, Randomized Trial
J. Clin. Endocrinol. Metab., August 1, 2008; 93(8): 2984 - 2990.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
P. U. Freda, L. Katznelson, A. J. van der Lely, C. M. Reyes, S. Zhao, and D. Rabinowitz
Long-Acting Somatostatin Analog Therapy of Acromegaly: A Meta-Analysis
J. Clin. Endocrinol. Metab., August 1, 2005; 90(8): 4465 - 4473.
[Abstract] [Full Text] [PDF]


Home page
Postgrad. Med. J.Home page
Z Merza
Modern treatment of acromegaly
Postgrad. Med. J., April 1, 2003; 79(930): 189 - 194.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
J. J. Kopchick, C. Parkinson, E. C. Stevens, and P. J. Trainer
Growth Hormone Receptor Antagonists: Discovery, Development, and Use in Patients with Acromegaly
Endocr. Rev., October 1, 2002; 23(5): 623 - 646.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
P. U. Freda
Somatostatin Analogs in Acromegaly
J. Clin. Endocrinol. Metab., July 1, 2002; 87(7): 3013 - 3018.
[Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
N. R. Biermasz, H. van Dulken, and F. Roelfsema
Ten-Year Follow-Up Results of Transsphenoidal Microsurgery in Acromegaly
J. Clin. Endocrinol. Metab., December 1, 2000; 85(12): 4596 - 4602.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1999 by The Endocrine Society